InspireMD (NASDAQ: NSPR) is one of 90 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it weigh in compared to its peers? We will compare InspireMD to similar businesses based on the strength of its institutional ownership, profitability, earnings, analyst recommendations, risk, dividends and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for InspireMD and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InspireMD 0 0 0 0 N/A
InspireMD Competitors 181 1175 2558 90 2.64

As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 8.00%. Given InspireMD’s peers higher probable upside, analysts plainly believe InspireMD has less favorable growth aspects than its peers.

Volatility & Risk

InspireMD has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, InspireMD’s peers have a beta of 1.07, indicating that their average stock price is 7% more volatile than the S&P 500.

Institutional and Insider Ownership

66.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 11.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


This table compares InspireMD and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
InspireMD -358.44% -136.76% -94.77%
InspireMD Competitors -126.62% -36.82% -9.89%

Valuation & Earnings

This table compares InspireMD and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
InspireMD N/A N/A -0.16
InspireMD Competitors $1.06 billion $130.46 million 208.73

InspireMD’s peers have higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


InspireMD peers beat InspireMD on 7 of the 8 factors compared.

About InspireMD

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Receive News & Ratings for InspireMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD Inc and related companies with's FREE daily email newsletter.